Psychedelics are rapidly gaining ground as an intervention of interest for severe
mood and anxiety disorders. The focus for most of this research is for patients who
have failed four or fewer adequate interventions. Few trials of any intervention have
looked at patients with depression who have failed more than four treatments in the
current episode. This is a pilot study looking at the open label administration of
25 mg of synthetic psilocybin in ten patients with documented failures of at least
five treatments in the current depressive episode.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Biological PsychiatryAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
Article info
Identification
Copyright
© 2022 Published by Elsevier Inc.
